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ABSTRACT By immunizing prion knockout mice
(Prnp2/2) with recombinant murine prion protein (PrPc), we
obtained a panel of mAbs specific for murine PrPc. These
mAbs can be applied to immunoblotting, cell surface immu-
nofluorescent staining, and immunohistochemistry at light
and electron microscopy. These mAbs recognize both the
normal (PrPc) and protease-resistant (PrPres) isoforms of
PrP. Some mAbs are species restricted, while others react with
PrP from a broad range of mammals including mice, humans,
monkeys, cows, sheep, squirrels, and hamsters. Moreover,
some of the mAbs selectively recognize different PrP glyco-
forms as well as the metabolic fragments of PrPc. These newly
generated PrPc antibodies will help to explore the biology of
PrPc and to establish the diagnosis of prion diseases in both
humans and animals.
Prion diseases, or transmissible spongiform encephalopathies,
are neurodegenerative disorders that affect both humans and
animals (1–7). All prion diseases are believed to share the same
basic pathogenic mechanism that involves the conversion of
the normal cellular prion protein (PrPc) into a form that is
infectious, insoluble in nonionic detergents, and partially
resistant to proteases (PrPres) (8–10). PrPc and PrPres share an
identical amino acid sequence. The conversion of PrPc to PrPres
may involve a conformational change of PrPc from a predom-
inantly a-helical form to a b-sheet structure (11–14). The
accumulation of PrPres in the brain is a cardinal feature of the
prion disease pathology. However, the conditions that trigger
and determine the conversion of PrPc to PrPres remain unclear.
One approach to the study of the PrPc to PrPres conversion is
offered by experimental models of inherited prion diseases.
Since many of the pathogenic mutations of the PrP gene
(PrPM) have high penetrance, it is likely that the change in
PrPM metabolism plays an important role in determining the
conversion of PrPM into PrPres. Detailed studies on cell models
of inherited prion diseases have underlined the complexity and
the diversity of the metabolic changes affecting the PrPM (15,
16).
Currently, there is one mAb that reacts with PrP is available
commercially (17), however, to understand the biology of PrP
and the pathogenesis of prion diseases requires an extensive
library of well characterized antibodies to PrP (16). A collec-
tion of diverse mAbs would allow identification of the different
metabolic products of PrPc, PrPM and PrPres providing new
insights into the mechanism of prion conversion. Ultimately,
these mAbs will facilitate the diagnosis of prion diseases in
humans and animals.
We immunized prion knockout mice (Prnp2/2) with re-
combinant murine PrPc to obtain a panel of mAbs specific for
PrPc and PrPres. These mAbs crossreact with PrPc from other
species of mammals including humans, monkeys, cows, sheep,
hamsters, and squirrels. Some selectively recognize PrP ac-
cording to the degree of glycosylation and size of the metabolic
products. Therefore, this panel of mAbs will be useful for
characterizing and localizing normal, mutant, and pathogenic
PrP.
MATERIALS AND METHODS
Animals and the Generation of mAbs. The creation of
129/Ola Prnp2/2 mice has been described in detail (18).
Recombinant murine PrP was prepared and purified as de-
scribed (19). Prnp2/2mice were immunized with recombinant
murine PrPc in complete Freund’s adjuvant. After boosting
three times with the corresponding antigen in incomplete
Freund’s adjuvant, spleen cells from one of the immunized
Prnp2/2 mice were fused with a myeloma, SP2/0, to create
hybridomas using a conventional protocol (20). We used an
ELISA to screen for potential anti-PrPc mAbs. Briefly, ELISA
plates were coated with 1 mg/ml purified murine PrPc proteins
overnight. Plates were then blocked with 3% BSA. One
hundred microliters of culture supernatant was added to each
well for 30 min at 37°C. After washing, a goat anti-mouse
horseradish peroxidase-labeled Ig antibody (Amersham) was
added for 30 min at 37°C. The reaction was visualized by
3,39,5,59 tetramethylbenzidine (Sigma) for 30 min at room
temperature and blocked with 1 M sulfuric acid. Of the 1000
viable clones tested, 79 positive clones were identified in the
first screening. In subsequent screening, 37 clones retained
their specificity. Six of these clones (2F8, 5B2, 6G9, 8C6, 8H4,
and 9H7) were chosen for further studies.
Immunof luorescent Staining. Cultured, parental PrPc-
negative human neuroblastoma cell line M17 and a human
neuroblastoma M17 cell line that was transfected with a
normal human PrPc gene (15) were harvested and washed with
washing medium (PBS supplemented with 5% new born calf
serum, 0.1% NaN3, pH 7.4). A single-cell suspension (1 3
106/ml) was incubated with affinity-purified mAbs or an iso-
type control antibody on ice for 45 min. Cells were washed
three times with washing medium and 25 ml of f luorescein
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isothiocyanate-conjugated goat anti-mouse IgG antibody was
added for 45 min on ice. Finally, samples were washed and
fixed with 1% paraformaldehyde. Cells were analyzed in a
FACScan (Becton Dickinson). At least 5,000 cells were ana-
lyzed per sample.
Protein Studies and Immunoblotting. Brain tissue from
different animals was homogenized in 9 vol of lysis buffer [100
mM sodium chloride, 10 mM EDTA, 0.5% Nonidet P-40, 0.5%
sodium deoxycholate, 10 mM Tris (pH 7.4), and 2 mM
phenylmethylsulfonyl f luoride]. For deglycosylation experi-
ments, samples were treated with N-glycosidase F (PNGase-F)
[1000 units in 1% Nonidet P-40 and 25 mM sodium phosphate
(pH 7.5)] as described (21). Proteins were separated in 12%
polyacrylamide gels and then transferred to Immobilon P
(Millipore) for 2 hr at 60 V. Membranes were incubated
overnight at 4°C with the different mAbs. The blots were
developed with an enhanced chemiluminescence system (Am-
ersham).
Immunohistochemistry. Paraffin sections of infected brain
grafts from a transgenic mouse overexpressing PrPc (Tg20)
mice implanted in the ventricular wall of a Prnp2/2 mouse
were prepared as described (22, 23). Sections were processed
for immunostaining after hydrolytic autoclaving (24). The
sections were deparaffinized, rehydrated, and immersed in
98% formic acid for 1 hr at room temperature. Endogenous
peroxidase was blocked by immersion in 8% hydrogen perox-
ide in methanol for 10 min. Sections were completely im-
mersed in 1.5 mM HCl and autoclaved at 121°C for 10 min.
After rinsing, they were incubated with the different mAbs. A
goat anti-mouse Ig antibody and peroxidase-antiperoxidase
was used to detect bound mouse mAb (Sternberg–Meyer,
Jarrettsville, MD). Diaminobenzidine tetrahydrochloride was
used to visualize the immunoreactivity. Paraffin sections from
the brain of a patient with Creutzfeldt-Jakob disease (CJD)
were processed and stained the same way.
Electron Microscopy Immunohistochemistry. Neuroblas-
toma cell cultures (wild type/M) were fixed in 2.5% glutaral-
dehyde in 0.1 M phosphate buffer (pH 7.4) for 90 min, washed
in TBS [0.1 M Tris (pH 7.5) and 0.15 M NaCl], scraped with
a rubber policeman, and then centrifuged at 500 3 g for 10 min
at 4°C. The pellet was embedded in 1.5% agarose and cut in
small oriented blocks under the light microscope using a razor
blade. The floating blocks were immersed in 0.1% Triton
X-100 in Tris-buffered saline for 10 min, blocked with 10%
nonfat dry milk for 30 min, and incubated with the 8H4 mAb
(1:50) overnight at 4°C in TBS, 0.1% Tween 20, 1% normal
goat serum, and 1% BSA. The 8H4 mAb was omitted in
negative controls. After washes in TBS the blocks were incu-
bated with 5 nm of gold-conjugated goat anti-mouse IgG
(Auro Probe; Amersham) for 2 hr at room temperature. The
blocks are then fixed in 2.5% glutaraldehyde and postfixed in
1% OsO4 for 1 h, dehydrated in alcohol, and embedded in
Spurr. Ultrathin sections were cut with a ultramicrotome
(Ultracut FC4; Reichert), stained with uranyl acetate and lead
citrate, and examined with a JEOL 100 electron microscope.
For cryosections cells were fixed and scraped as described
above. Pellet was incubated in 30% polyvinylpyrrolidone and
2.3 M sucrose, placed on specimen stubs, and frozen in liquid
nitrogen. Ultrathin cryosections (approximately 120-nm thick)
were cut on glass knives in an ultracryomicrotome (Teichart
ultracut S; Leica, Deerfield, IL). The sections were then placed
on carbon and Formvar-coated grids and immunostained as
described earlier.
RESULTS
Immunoblotting of Human and Murine PrPc. We separated
the mAbs according to the pattern of immunoreactivity with
native and deglycosylated PrPc on immunoblots: mAbs 8H4,
8C6, 9H7, and 2F8 recognize full-length and truncated forms
of PrPc; mAb 5B2 reacts only with the full-length PrPc; and
mAb 6G9 is glycosylation specific. mAb 6G9 selectively fails to
recognize the highly glycosylated form of PrPc. None of the
mAbs react with the brain homogenate from the Prnp2/2
mouse, confirming the specificity of all of the mAbs for PrPc.
In humans and mice, mAb 8H4 representative of the first
group reacts equally with the three known PrPc glycoforms; the
unglycosylated form which migrates at 27 kDa, the interme-
diate form, thought to be monoglycosylated, which migrates at
28–30 kDa; and the highly glycosylated forms which migrate as
a band spanning 33–42 kDa (Fig. 1). In addition, mAb 8H4
reacts with two bands at 25 kDa and 18 kDa, respectively.
These two bands are known to contain the PrPc forms trun-
cated at the N terminus which are generated during normal
processing of PrPc (Fig. 1). The 18-kDa protein is likely to be
the unglycosylated form of the 25-kDa fragment, since, after
deglycosylation, mAb 8H4 reacts only with the 18- and 27-KDa
proteins, the latter corresponding to the full-length unglyco-
sylated form. The only difference in mAb 8H4 immunoreac-
tivity between human and mouse PrPc is the reduced affinity
for the mouse 25-kDa fragment (Fig. 1). Among the other
mAbs of this group, 8C6 and 9H7 differ from 8H4 in the lack
of immunoreactivity with the 25-kDa truncated form. Further-
more, mAb 2F8 has a weaker reaction with the full-length
forms and, in addition, fails to react with the truncated forms
in the mouse (data not shown).
mAb 5B2 reacts strongly with the highly glycosylated and
intermediate isoforms of human and mouse PrPc but reacts
weakly with the unglycosylated isoform (Fig. 1). mAb 5B2 does
not react with the truncated PrPc recognized by the previous
group of mAbs. mAb 5B2 reacts strongly with PrPc after
deglycosylation of PrPc with endoglycosidase F (Fig. 1).
mAb 6G9 consistently failed to react with the highly glyco-
sylated PrPc but reacts with all of the other forms, including the
truncated forms, from both humans and mice (Fig. 1). Upon
digestion with endoglycosidase F, mAb 6G9 reacts with both
27-kDa and 18-kDa proteins (Fig. 1).
FIG. 1. Human and mouse brain proteins immunoblotted with
mAbs to PrPc raised in this study. Prnp2/2, PrP knockout mice; H, I,
U, diglycosylated,monoglycosylated, unglycosylated full-length PrP; I
trunc and U trunc, monoglycosylated and unglycosylated truncated
PrP. mAbs 8H4 and 6G9 react with all PrP forms while mAb 5B2 only
reacts with the full-length forms. mAb 6G9 fails to recognize the
diglycosylated forms. None of the mAbs react with any protein from
the brain of PrP2/2 mice which does not express PrP.
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Reactivity with PrPc from other Mammals. In the macaque,
spider, and Capuchin monkeys, mAb 8H4 from the first group
reacts with the three full-length glycoforms and the 25-kDa
and 18-kDa truncated fragments similar to that observed in
humans and mice (Fig. 2). However, two additional, slightly
different patterns can be seen in other animals. In the chim-
panzee, cow, sheep, and squirrel, mAb 8H4 appears to react
less with the intermediate form and the 25-kDa truncated
form. In the squirrel monkey, mAb 8H4 recognizes weakly the
highly glycosylated PrPc. mAb 2F8 recognizes PrPc from all of
the animal species studied reproducing a pattern which re-
sembles that of mAb 8H4. Among the other mAbs of this
group, 8C6 and 9H7 show a generally weaker and more
species-dependent reaction than 8H4. mAb 2F8 recognizes
PrPc from all of the animal species examined with a pattern
similar to that of mAb 8H4 (data not shown).
mAb 5B2 shows a strong reactivity with all of the full-length
forms as in humans and mice. However, mAb 5B2 appears to
recognize the intermediate and the unglycosylated forms less
well than the highly glycosylated form in the other species.
mAb 5B2 does not recognize the truncated forms in any of the
tested species (Fig. 2).
The distinctive characteristic of mAb 6G9 is the lack of a
reaction with the highly glycosylated form in all species. mAb
6G9 also fails to react with PrPc from the squirrel monkey and
the squirrel. Moreover, in all species of animals tested, mAb
6G9 recognizes the intermediate form as one band rather than
two bands as demonstrated by the other mAbs (Fig. 2).
When the patterns of immunoreactivity of the mAb panel in
the various species are compared, the overall immunoreactiv-
ity is higher with the human and mouse PrPc and lower with
the squirrel monkey PrPc than with that of other species. As to
the individual PrPc forms, the highly glycosylated form is
generally well recognized by most of the mAbs across species,
but there are differences in immunoreactivity for the inter-
mediate, unglycosylated, and truncated forms. These forms are
well recognized in humans and less well recognized in cow,
sheep, squirrel, squirrel monkey, and chimpanzee, perhaps
because these forms are underrepresented in these species.
The mobility of the highly glycosylated and the intermediate
forms are also heterogeneous. PrPc from the cow and squirrel
monkey migrates slower and PrPc from the spider monkey
migrates faster than all other species because of the insertion
or deletion of one of the octapeptide repeats, respectively.
PrPc Epitopes Recognized by the mAb Panel. mAbs 8H4,
8C6, 9H7, and 2F8, the four mAbs of the first group, must be
directed to an epitope located in the C-terminal region of PrPc
between residues 145 and 220 (Fig. 3) for two reasons: (i) they
react with the truncated PrPc forms which have been shown to
be generated by the cleavage of the full-length PrPc at amino
acid 111/112 (25), and (ii) they do not react with either the
synthetic human PrP peptide 220–231 or with the mutant PrP
expressed in neuroblastoma cells transfected with the 145 stop
codon PrP gene construct which is truncated at residue 145
(G.Z., R.B.P., P.G., and N. Singh, unpublished data). The
epitope recognized by 8H4 might be further deduced by the
lack of recognition of PrPc from the squirrel monkey. The
squirrel monkey carries two unique amino acid substitutions in
the PrP sequence at residues 166 and 189.
mAb 5B2 does not immunoreact with the truncated PrPc
forms and also fails to recognize the recombinant protein with
amino acids 90–231 (ref. 26 and unpublished results). There-
fore, the epitope recognized by mAb 5B2 resides at the
N-terminal half, amino acids 23–90 of the molecule. This
interpretation is supported by our recent finding that mAb 5B2
binds specifically to a synthetic peptide corresponding to
amino acids 23–40 of the PrP (results not shown).
The epitope bound by mAb 6G9 is most likely to reside at
or very close to the N-glycosylation site that in humans is
FIG. 3. Epitope mapping of anti-PrPc mAbs. Diagrammatic rep-
resentation of mAb epitope topography in the 23–220 PrPc sequence.
p, indicates the human PrPc residues 159 and 182, respectively, which
correspond to 166 and 189, respectively, in the squirrel monkey.
FIG. 4. Expression of PrPc on the surface of transfected human
neuroblastoma cell line analyzed by FACScan. Clear areas represent
staining of PrPc-negative parental M17 cells. Shaded areas represent
staining of PrP-positive transfectants. mAb 5B2 stains less intensely
than other mAbs probably because it does not react with truncated
PrPc forms.
FIG. 2. Brain proteins from different mammals immunoblotted
with mAbs to PrPc. Abbreviations as in the legend to Fig. 1. The three
mAbs react well with all species except the squirrel monkey, which is
recognized poorly by both mAb 8H4 and 6G9 and the squirrel which
is not recognized by 6G9. Both 8H4 and 6G9 but not 5B2 recognize
the truncated forms in most species. mAb 6G9 fails to react with the
H form in all species examined.
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located at residue 181. This inference is based on the finding
that mAb 6G9 does not recognize the highly glycosylated PrPc
form in which both glycosylation sites are occupied. The
epitope localization at or close to human PrP residue 181 is
further supported by the lack of reactivity of mAb 6G9 with all
forms of PrPc from the squirrel monkey. This PrPc carries an
amino acid substitution at residue 189, corresponding to
residue 182 in humans (27).
Immunofluorescent Staining and Immunocytochemistry of
PrPc or PrPres in Unfixed and Fixed Cells and Tissues. All six
of our mAbs reacted with PrPc expressed at the surface of
living human neuroblastoma cell transfectants overexpressing
PrPc. The fluorescence-activated cell sorting profiles of six of
these mAbs are shown in Fig. 4. The staining intensity of mAb
5B2 is less than that of all of the other mAbs, suggesting that
the epitope recognized by 5B2 may be less abundant. This
observation is in good accordance with our earlier observation
that mAb 5B2 does not recognize the truncated PrPc forms
which can account for approximately '30% of the total PrPc
at the cell surface (N. Singh, G.Z., R.B.P., and P.G., unpub-
lished results). The same panel of mAbs did not stain the
parental M17 cell line in which PrPc is not detectable.
Brain tissues from Tg20 transgenic mice that had been
implanted in Prnp2/2 mice and then infected with PrPsc (22,
23) were processed and stained with mAb 8H4. mAb 8H4
intensely immunostained the infected murine implants, espe-
cially their neuropils and the surface of neurons (Fig. 5A). A
similar result was obtained with mAbs 2F8, 5B2, 8C6, 9H7, and
6G9 although the intensity of the staining of some of these
antibodies was less than that of mAb 8H4 (results not shown).
We also stained tissue sections from fixed cerebellar cortex
from a patient with CJD. All mAbs except for mAb 6G9 also
immunostained PrPsc in the three cortical layers of the cere-
bellum in the affected CJD subject with a plaque-like pattern
(Fig. 5B). These anti-PrPc mAbs did not stain unaffected
regions of the brain. The procedures of hydrolytic autoclaving
used to enhance staining of PrPsc may have destroyed the
epitopes present in normal PrPc. Furthermore, mAbs 8H4,
5B2, and 2F8 also react with the PrPc present in fixed and
permeabilized neuroblastoma transfectants (Fig. 5C). As re-
ported earlier with another antibody, staining is seen in the
cytoplasm and is most pronounced in the Golgi apparatus (28).
Immunogold Electron Microscopy. To identify the cellular
organelle in which the conversion of PrPc to PrPres takes place,
we need antibodies suitable for electron microscopic immu-
nolocalization in well preserved cells and tissues. Neuroblas-
toma transfectants were immunostained with mAb 8H4 and
5B2. mAb 8H4 immunolocalizes PrPc on the cell surface (Fig.
6 A and B). mAb 5B2 labeled the Golgi compartment con-
firming our earlier observation using immunohistochemistry
(Fig. 6C).
DISCUSSION
Immunochemical tests are the most efficient and reliable
diagnostic procedures for identifying humans and animals
affected by prion diseases. Only one mAb, 3F4, has been
extensively used to date. It reacts with an epitope residing
between amino acids 109 and 112 (17). mAb 3F4 does not
recognize the C-terminal PrPc fragments which are generated
during the normal metabolism of PrP or the small pathological
fragments containing the C-terminal region (26). Further-
more, mAb 3F4 detects PrPc in humans and hamster but not
in mouse, cow, sheep, Capuchin monkey, and squirrel. This is
FIG. 5. Immunohistochemistry of PrPres in mouse brain, PrPres in
CJD brain, and PrPc in a human neuroblastoma cell line. (A) Infected
brain grafts from a transgenic mouse overexpressing PrPc, Tg20 mice,
implanted in the ventricular wall of a Prnp2/2 mouse. Paraffin
sections were processed and stained with mAb 8H4. mAb 8H4 only
stained the neurografts (arrows). (320.) (B) Cerebellar tissues from
the brain of a patient with CJD were processed and stained with mAb
8H4. Plaque-like PrP deposits (arrows) are diffusely distributed in the
molecular and granular layers of the cerebellum. (3 150.) (C) A
neuroblastoma cell line transfected with a construct expressing normal
human PrPc was stained with 8H4. PrPc is distributed in the intracel-
lular compartment with a Golgi-like distribution. (3430.)
FIG. 6. Immunoelectron microscopy of neuroblastoma cells. (A)
Gold particles line up the cell surface. (339,000.) (B) Same as A.
(378,000.) (C) Gold particles are distributed over the Golgi compart-
ment. (3 59,000.)
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a significant limitation since transgenic mice are currently the
most widely used animal models for studying prion diseases.
The ability to detect cow and squirrel PrP will also help
document the potential transmission of prion diseases from
these animals to humans and will allow routine diagnosis of
prion diseases in a number of mammals (6, 29). Therefore, a
panel of anti-PrP mAbs which recognize epitopes distributed
over the PrPc will permit detection of PrPc and PrPres as well
as monitoring of PrPc processing under normal or pathological
conditions.
The mAbs raised in our study are directed to distinct
epitopes throughout the 23–231 PrPc fragment. One of the
mAbs, mAb 5B2, reacts with the N terminus of PrPc. The
remaining mAbs recognize the PrPc C-terminal fragments as
well as other C-terminal fragments generated under patho-
logical conditions. Moreover, our mAbs also recognize PrPc
from many different species of mammals including humans,
mouse, cattle, sheep, squirrel, and hamster. Because our mAbs
recognize PrPc from evolutionary diverse species, it is likely
that these mAbs will also react with PrPc from other mammals.
We have shown that a single amino acid substitution might
compromise the epitope recognition by several mAbs; more
frequently when the substitutions are not conservative. For
example, mAb 6G9 selectively fails to recognize the squirrel
monkey PrPc which is the only known mammal with a Val at
PrP position 189 corresponding to the human PrP 182 residue.
Thus, since 6G9 also fails to recognize PrPc in the squirrel we
can also predict the presence of an amino acid substitution at,
or close to, the residue corresponding to the human residue 182
in this species whose PrPc has yet to be sequenced.
Some of the mAbs react differently with the various PrP
glycoforms. One mAb, 6G9, preferentially recognizes the
monoglycosylated and the unglycosylated forms but not the
highly glycosylated forms. In contrast, another mAb 8H4
recognizes all three isoforms equally well in humans and
macaque, spider, and Capuchin monkeys, but only two glyco-
forms from cow, sheep, and squirrel. These antibodies will be
useful in comparing glycoforms in different species and in
identifying the individual glycoforms under conditions in
which they are altered (28).
The study of PrPc metabolism and the PrPc to PrPres
conversion has been impaired by the difficulty to identify
cellular locales of PrPc processing and conversion (30). All of
the mAbs we developed are suitable for immunohistochemis-
try of PrPc and PrPres on fixed and unfixed tissues. More
important, we have been able to use immunoelectron micros-
copy with mAbs 8H4 and 5B2 to demonstrate the presence of
the prion protein on the cell surface and in the Golgi apparatus
of neuroblastoma cells fixed in glutaraldehyde. The ability to
conduct ultrastructural immunolocalization following glutar-
aldehyde fixation is especially critical. Glutaraldehyde is the
fixative of choice for electron microscopy but commonly
cannot be used in immunocytochemistry because such treat-
ment denatures the epitopes. Thus, our mAbs should provide
an opportunity to map the ultrastructural distribution of the
PrPc and PrPres isoforms in pathological tissues.
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